BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23256105)

  • 1. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents.
    Bello SL; Serafino L; Bonali C; Terlizzi N; Fanizza C; Anecchino C; Lapaldula G
    Reumatismo; 2012 Dec; 64(5):299-306. PubMed ID: 23256105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
    Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
    Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B
    Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study.
    Espiño-Lorenzo P; Manrique-Arija S; Ureña I; Jiménez-Núñez FG; López-Lasanta M; Romero-Barco CM; Belmonte-López MA; Irigoyen MV; Fernández-Nebro A
    Reumatol Clin; 2013; 9(1):18-23. PubMed ID: 22938792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biologicals in the treatment of rheumatic diseases].
    Scherer HU; Burmester GR
    Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.
    Modesti V; Ramonda R; Ortolan A; Lorenzin M; Lo Nigro A; Frallonardo P; Oliviero F; Campana C; Punzi L
    Scand J Rheumatol; 2012; 41(6):490-1. PubMed ID: 22985209
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GISEA: an Italian biological agents registry in rheumatology.
    Lapadula G; Ferraccioli G; Ferri C; Punzi L; Trotta F;
    Reumatismo; 2011 Nov; 63(3):155-64. PubMed ID: 22257916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion.
    DI Franco M; Paradiso M; Ceccarelli F; Scrivo R; Spinelli FR; Iannuccelli C; Valesini G
    J Rheumatol; 2012 Jan; 39(1):41-5. PubMed ID: 22045840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
    Sichletidis L; Settas L; Spyratos D; Chloros D; Patakas D
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1127-32. PubMed ID: 17044206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.